Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Stroke: The Issue is Finally Settled
Keywords:
cryptogenic stroke, paradoxical embolism, patent foramen ovale, percutaneous closureAbstract
Based on newer data from randomized controlled trials and meta-analyses, the previously controversial and highly debated issue of patent foramen ovale (PFO) closure in patients with cryptogenic stroke is finally settled in favor of closure over medical therapy for the secondary prevention of cryptogenic stroke attributable to paradoxical embolism. One PFO closure device finally received FDA approval in October 2016. Rhythmos 2017; 12(4):60-62.
Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
